Biological Products, (No Diagnostic Substances) · DE · CIK 914475
Neurocrine Biosciences discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders
Comparable business profile · signals at a glance
In the 90 days to Jan 16, 2026: 7 sold $14.6M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 16, 2026 | Gano KyleChief Executive Officer | Sell | 34,588 | $132.70 | $4.6M |
| Jan 16, 2026 | Gano KyleChief Executive Officer | Sell | 1,812 | $132.71 | $240K |
| Dec 16, 2025 | Norwalk Leslie VDirector | Sell | 1,190 | $155.09 | $185K |
| Dec 15, 2025 | Norwalk Leslie VDirector | Sell | 5,000 | $152.23 | $761K |
| Dec 8, 2025 | Lippoldt DarinChief Legal Officer | Sell | 4,376 | $159.65 | $699K |
| Dec 3, 2025 | Lyons Gary ADirector | Sell | 15,000 | $152.61 | $2.3M |
| Nov 28, 2025 | Benevich EricChief Commercial Officer | Sell | 5,970 | $151.74 | $906K |
| Nov 25, 2025 | Morrow George JDirector | Sell | 15,000 | $143.37 | $2.2M |
| Nov 5, 2025 | Rastetter William HDirector | Sell | 18,000 | $151.82 | $2.7M |
| Nov 4, 2025 | Gano KyleChief Executive Officer | Sell | 300 | $141.97 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗